Repros Therapeutics (RPRX) Poised to Open Lower
- DuPont (DD) Tops Q4 EPS by 9c; Sees Merger Closing in First Half
- Barclays Downgrades Apple (AAPL) to Equalweight, Concerned India/China Will not Emerge As Growth Catalysts
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- SAP (SAP) Q4 IFRS Revenues Rises 7%, Boosts 2020 Outlook
- Oppenheimer Downgrades Energous Corp (WATT) to Perform
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Repros Therapeutics (NASDAQ: RPRX) shares were poised to open sharply lower Friday morning, with shares indicated down 28%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stocks with Implied Volatility Movement
- Options with increasing volume
- Stocks with increasing put volume on January 23
Create E-mail Alert Related CategoriesTrader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!